PHI-0241- A PHASE I/II CLINICAL TRIAL OF PS-341, A PROTEASOME INHIBITOR, IN C

PHI-0241-蛋白酶体抑制剂 PS-341 的 I/II 期临床试验

• 批准号: 7731382
• 负责人: Jeffrey A Sosman
• 金额: $ 0.04万
• 依托单位: VANDERBILT UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-12-01 至 2007-09-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7731382
• 关键词: Clinical; Clinical Trials; Computer Retrieval of Information on Scientific Projects Database; Dose; Funding; Grant; Institution; Maximum Tolerated Dose; PS341 cpd; Phase; Phase I Clinical Trials; Proteasome Inhibitor; Research; Research Personnel; Resources; Source; United States National Institutes of Health; base; temozolomide

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Specific aims: define the optimal doses of temozolomide in combination with PS-341 based upon the optimal biologic dose and the maximum tolerated dose. describe any clinical antitumor activity observed in the Phase I trial.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 具体目标：根据最佳生物剂量和最大耐受剂量确定替莫唑胺与PS-341联合给药的最佳剂量。 描述I期试验中观察到的任何临床抗肿瘤活性。